Aspen Pharmacare to pay £8 million after colluding to rip off NHS

pharmafile | August 14, 2019 | News story | Research and Development Addison's disease, Aspen Pharmacare, CMA, NHS, pharma 

South African firm Aspen Pharmacare has agreed to pay £8 million to Britain’s NHS over a dispute about overpayment.

The Competition and Markets Authority (CMA) said the settlement follows an investigation into collusion between Aspen and rival firms to keep competitors to its Fludrocortisone 0.1 mg tablets off the market.

Aspen’s Fludrocortisone tablets are used to treat Addison’s disease, a rare hormonal disorder which affects the adrenal glands.

Aspen may also have to pay an additional £2.1 million in fines as part of a wider package, if the investigation concludes that the company broke the law. The CMA is also investigating the two other companies involved in the collusion.

Andrea Coscelli, the CMA’s chief executive, commented in suggesting it was “unacceptable for the NHS – and the taxpayers who fund it – to have to pay millions of pounds more than they should for this life-saving drug.”

Louis Goss

Related Content


NHS given guidance on offering genetic testing to stroke patients

The NHS has been given draft guidance on offering gene tests to patients who have …

NICE recommends Hepcludex for NHS use to treat aggressive form of viral hepatitis

The National Institute for Health and Care Excellence (NICE) has recommended Hepcludex (bulevirtide) for the …


NHS in Scotland makes rheumatoid arthritis drug available

The Scottish Medicines Consortium (SMC) have recommended the use of Galapagos UK’s JYSELECA® (filgotinib) for …

Latest content